CARAMBA SIGNED
SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0CARAMBA project word cloud
Explore the words cloud of the CARAMBA project. It provides you a very rough idea of what is the project "CARAMBA" about.
Project "CARAMBA" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Project website | http://www.caramba-cart.eu |
| Total cost | 6˙097˙875 € |
| EC max contribution | 6˙097˙875 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SC1-2017-Two-Stage-RTD |
| Funding Scheme | RIA |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-01-01 to 2022-04-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | DE (WURZBURG) | coordinator | 2˙021˙250.00 |
| 2 | OSPEDALE SAN RAFFAELE SRL | IT (MILANO) | participant | 893˙125.00 |
| 3 | DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH | DE (MANNHEIM) | participant | 685˙000.00 |
| 4 | UNIVERSIDAD DE NAVARRA | ES (PAMPLONA) | participant | 624˙375.00 |
| 5 | T-CURX GMBH | DE (WURZBURG) | participant | 503˙750.00 |
| 6 | CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE | FR (LILLE) | participant | 384˙375.00 |
| 7 | BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL | DE (LANGEN) | participant | 342˙875.00 |
| 8 | ARTTIC | FR (PARIS) | participant | 327˙500.00 |
| 9 | NBE-THERAPEUTICS AG | CH (BASEL) | participant | 200˙000.00 |
| 10 | MYELOMA PATIENTS EUROPE AISBL | BE (Charleroi) | participant | 115˙625.00 |
Map
Project objective
CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy. Myeloma is associated with a substantial socioeconomic burden and there is a strong demand by patients, their families and caregivers for a curative myeloma treatment. The CARAMBA investigators will conduct a phase I/II clinical trial of immunotherapy with patient-derived T cells that are engineered to express a synthetic chimeric antigen receptor (CAR) specific for the myeloma antigen SLAMF7. SLAMF7 is uniformly expressed on all myeloma cells in every patient, and SLAMF7 CAR-T cells will be equally effective in women and men. The efficacy and safety of SLAMF7 CAR-T cells has been validated by the coordinator in comprehensive pre-clinical testing which highlighted their unprecedented curative potential. SLAMF7 CAR-T cells have received an orphan designation for the indication multiple myeloma by the EC. The successful conduct, rapid and complete recruitment into the clinical trial is ensured by participation of 4 clinical myeloma centres of excellence in 4 EU member states, and the largest myeloma patient advocacy group in Europe, MPE. The SME partners in CARAMBA are prepared to develop the SLAMF7 CAR product all the way to market authorization. CAR-T cell therapy has been recognized as a ‘Breakthrough Therapy’ and clinical proof-of-concept obtained with CD19 CAR-T cells in leukemia and lymphoma. CARAMBA is building on novel and proprietary, cutting-edge CAR technologies including virus-free Sleeping Beauty CAR gene-transfer from DNA minicircles which substantially reduces the cost of CAR-T cell manufacturing, making it an economically viable and sustainable medicinal product. We are confident, that if funded, CARAMBA will accomplish its objective to establish the role of CAR-T cell therapy as a therapeutically effective, commercially attractive and socioeconomically desirable treatment in myeloma and other rare diseases.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Michael Hudecek, Zoltán Ivics Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system published pages: 100-108, ISSN: 0959-437X, DOI: 10.1016/j.gde.2018.06.003 |
Current Opinion in Genetics & Development 52 | 2019-09-30 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARAMBA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CARAMBA" are provided by the European Opendata Portal: CORDIS opendata.